Factor VIII antibody (Coagulation Factor VIII)

Details for Product anti-F8 Antibody No. ABIN112268, Supplier: Log in to see
Antigen
  • fb61d02
  • wu:fb61d02
  • Cf-8
  • Cf8
  • FVIII
  • AHF
  • DXS1253E
  • F8B
  • F8C
  • HEMA
  • coagulation factor VIIi
  • coagulation factor VIII
  • coagulation factor VIII, procoagulant component
  • f7i
  • F8
Reactivity
Human
309
69
52
27
11
2
2
2
2
1
1
1
Host
Mouse
171
136
27
4
1
Clonality (Clone)
Monoclonal ()
Conjugate
This Factor VIII antibody is un-conjugated
19
18
14
7
7
6
5
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
Application
Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro)), Western Blotting (WB)
219
162
51
43
39
25
22
13
13
12
6
6
3
3
2
2
2
2
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen Human factor VIII antigen
Clone MH104
Isotype IgG2a
Specificity MH104 is specific for human factor VIIIc, a 300 kDa protein present in plasma in a complex with von Willebrandt factor. Involved in the clotting cascade (activated by thrombin) by forming a complex with factor IXa, calcium, and phospholipids. Elevated levels of factor VIII have been associated with acute and chronic liver diseases, vascular disorders, diabetes and with acutephase reactions.
Purification Protein A affinity chromatography
Background Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50 % of patients have severe hemophilia A with F8C activity less than 1 % of normal, they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10 % of patients, F8C activity is 2-5 % of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40 % of patients, is associated with F8C activity of 5-30 % and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5 %) that have considerable amount of F8C in their plasma (at least 30 % of normal), but the protein is nonfunctional, i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.Synonyms: AHF, Antihemophilic factor, F8C, Procoagulant component
Gene ID 2157
NCBI Accession NP_000123
UniProt P00451
Application Notes ELISA: 1: 5,000, detection and quantitation of human factor VIII. Immunoblotting. Immunohistochemistry on frozen sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Reconstitution Restore in 1 mL dist. water
Buffer PBS, pH 7.4 containing 0.09 % NaN3, 0.5 % BSA
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice This product is photosensitive and should be protected from light
Storage 4 °C
Storage Comment Prior to and following reconstitution store the antibody undiluted at 2-8 °C. DO NOT FREEZE!
Background publications Stel, van der Kwast, Veerman: "Detection of factor VIII/coagulant antigen in human liver tissue." in: Nature, Vol. 303, Issue 5917, pp. 530-2, 1983 (PubMed).